Author

Jonathan A. Pachter

Verastem (United States)ORCID 0000-0002-0263-474XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Adam J. DupuyiD· 1 shared Adeline A. Hawkins· 1 shared Afshin VarzavandiD· 1 shared Ana Orive-RamosiD· 1 shared Beau BaarsiD· 1 shared Bijaya GaireiD· 1 shared Christopher S. StippiD· 1 shared Christos AdamopoulosiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam J. DupuyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

Ana Orive-Ramos, Bijaya Gaire, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Ziyue Kou, Evangelia Matenoglou, Sílvia Coma, Nayeli Gutiérrez, Kevin Mohammed, Stuart A. Aaronson, Jian Jun Jin, Tiphaine C. Martin, Ernesto Guccione, Evripidis Gavathiotis, , Poulikos I. Poulikakos

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

Cancer Discovery · Sep 29, 2026Peer-reviewedCancer Biology

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

Jesse D. Riordan, Teagan A. Nathanson, Afshin Varzavand, Adeline A. Hawkins, Rebekah M. Peplinski, Elizabeth C. Hannan, Faith A. Bibeau, Nathaniel J. Freesmeier, Madison C. Jilek, Silvia Coma, Jonathan A. Pachter, Adam J. Dupuy, Christopher S. Stipp

This study identifies FAK signaling as a critical target for overcoming Rac1-driven MAPK resistance in melanoma and shows that combining RAF/MEK and FAK inhibitors is effective.

Oncogene · Oct 18, 2025Peer-reviewedCancer Biology